Decvin Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 19-06-2024
- Paid Up Capital ₹ 1.27 M
as on 19-06-2024
- Company Age 31 Year, 7 Months
- Last Filing with ROC 31 Mar 2022
- Revenue 17.86%
(FY 2022)
- Profit 40.04%
(FY 2022)
- Ebitda 12.82%
(FY 2022)
- Net Worth 10.55%
(FY 2022)
- Total Assets 8.21%
(FY 2022)
About Decvin Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.27 M, as per Ministry of Corporate Affairs (MCA) records.
Nageswara Nimmagadda, Gokul Bommareddy, and Sai Bhimavarapu serve as directors at the Company.
- CIN/LLPIN
U24230TG1993PTC015712
- Company No.
015712
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 May 1993
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Decvin Laboratories Pvt. Ltd. offer?
Decvin Laboratories Pvt. Ltd. offers a wide range of products and services, including Bird Food, Poultry & Animal Food, Animal Feed, Animal Feed Supplement, Fish Foods, Vitamin E Selenium Supplement, Poultry Feed Supplements, Toxin Binder, Cattle Feed Supplement.
Who are the key members and board of directors at Decvin Laboratories?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nageswara Nimmagadda  | Director | 03-May-1993 | Current |
| Gokul Bommareddy | Director | 28-Aug-2000 | Current |
| Sai Bhimavarapu | Director | 30-Jan-2018 | Current |
Financial Performance of Decvin Laboratories.
Decvin Laboratories Pvt. Ltd., for the financial year ended 2022, experienced significant growth in revenue, with a 17.86% increase. The company also saw a substantial improvement in profitability, with a 40.04% increase in profit. The company's net worth Soared by an impressive increase of 10.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Decvin Laboratories?
In 2021, Decvin Laboratories had a promoter holding of 96.06% and a public holding of 3.94%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Decvin Laboratories?
Unlock and access historical data on people associated with Decvin Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Decvin Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Decvin Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
